Literature DB >> 11122726

Niacin dosing: relationship to benefits and adverse effects.

D M Capuzzi1, J M Morgan, O A Brusco, C M Intenzo.   

Abstract

Because of the original observation by Altschul et al., that nicotinic acid (niacin), not nicotinamide, in pharmacologic doses lowered human serum cholesterol levels, an avalanche of reports have been published over the past 45 years on the plasma lipid-regulating properties of this drug and its beneficial cardiovascular effects. A myriad of studies that have examined efficacy, safety, adverse effects, and pharmacologic properties of niacin rendered convincing evidence that niacin, used alone or combined with other agents, has favorable effects on serum lipoprotein regulation and on containment of atherothrombotic cardiovascular diseases. However, because of the unusual side effect profile of niacin and the availability of various formulations of this drug, niacin must be used prudently and with careful instruction and monitoring of patients. This review summarizes the pertinent and recent literature on niacin that impacts its therapeutic use. We also discuss some controversial issues and personal clinical experience and opinions on this topic.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122726     DOI: 10.1007/s11883-000-0096-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.967


  37 in total

1.  Results of recent large cholesterol-lowering trials and implications for clinical management.

Authors:  A M Gotto
Journal:  Am J Cardiol       Date:  1997-06-15       Impact factor: 2.778

2.  Lovastatin, nicotinic acid, and rhabdomyolysis.

Authors:  P Reaven; J L Witztum
Journal:  Ann Intern Med       Date:  1988-10-01       Impact factor: 25.391

3.  Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.

Authors:  D J Norman; D R Illingworth; J Munson; J Hosenpud
Journal:  N Engl J Med       Date:  1988-01-07       Impact factor: 91.245

4.  Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia.

Authors:  J L Vacek; G Dittmeier; T Chiarelli; J White; H H Bell
Journal:  Am J Cardiol       Date:  1995-07-15       Impact factor: 2.778

5.  The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study.

Authors:  A G Olsson; G Ruhn; U Erikson
Journal:  J Intern Med       Date:  1990-06       Impact factor: 8.989

6.  A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.

Authors:  J M McKenney; J D Proctor; S Harris; V M Chinchili
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

7.  Normalisation of the composition of very low density lipoprotein in hypertriglyceridemia by nicotinic acid.

Authors:  P Tornvall; A Hamsten; J Johansson; L A Carlson
Journal:  Atherosclerosis       Date:  1990-10       Impact factor: 5.162

8.  Fluvastatin with and without niacin for hypercholesterolemia.

Authors:  T A Jacobson; M M Chin; G J Fromell; L A Jokubaitis; L F Amorosa
Journal:  Am J Cardiol       Date:  1994-07-15       Impact factor: 2.778

9.  Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.

Authors:  L A Carlson; G Rosenhamer
Journal:  Acta Med Scand       Date:  1988

10.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.

Authors:  D H Blankenhorn; S A Nessim; R L Johnson; M E Sanmarco; S P Azen; L Cashin-Hemphill
Journal:  JAMA       Date:  1987-06-19       Impact factor: 56.272

View more
  14 in total

1.  The effects of combined treatment with niacin and chromium on the renal tissues of hyperlipidemic rats.

Authors:  Meliha Sengezer Inceli; Sehnaz Bolkent; M Mutluhan Doger; Refiye Yanardag
Journal:  Mol Cell Biochem       Date:  2006-11-24       Impact factor: 3.396

Review 2.  Management of dyslipidemia in women in the post-hormone therapy era.

Authors:  Lori Mosca
Journal:  J Gen Intern Med       Date:  2005-03       Impact factor: 5.128

3.  TRPV1 channels are involved in niacin-induced cutaneous vasodilation in mice.

Authors:  Heather L Clifton; Bora Inceoglu; Linlin Ma; Jie Zheng; Saul Schaefer
Journal:  J Cardiovasc Pharmacol       Date:  2015-02       Impact factor: 3.105

Review 4.  Pathophysiology and treatment of the dyslipidemia of insulin resistance.

Authors:  G Cohn; G Valdes; D M Capuzzi
Journal:  Curr Cardiol Rep       Date:  2001-09       Impact factor: 2.931

5.  Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic "power station".

Authors:  Laura Trapani; Marco Segatto; Valentina Pallottini
Journal:  World J Hepatol       Date:  2012-06-27

6.  Acute effects of a thermogenic nutritional supplement on cycling time to exhaustion and muscular strength in college-aged men.

Authors:  Ashley A Walter; Trent J Herda; Eric D Ryan; Pablo B Costa; Katherine M Hoge; Travis W Beck; Jeffery R Stout; Joel T Cramer
Journal:  J Int Soc Sports Nutr       Date:  2009-07-13       Impact factor: 5.150

7.  Combined effects of niacin and chromium treatment on vascular endothelial dysfunction in hyperlipidemic rats.

Authors:  N Niu; Y H Yu; Y Wang; L J Wang; Q Li; L M Guo
Journal:  Mol Biol Rep       Date:  2008-07-12       Impact factor: 2.316

Review 8.  Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes.

Authors:  Carles Cantó; Anthony A Sauve; Peter Bai
Journal:  Mol Aspects Med       Date:  2013-01-25

9.  Cystoid macular edema induced by low doses of nicotinic Acid.

Authors:  Daniela Domanico; Carmela Carnevale; Serena Fragiotta; Francesca Verboschi; Simona Altimari; Enzo Maria Vingolo
Journal:  Case Rep Ophthalmol Med       Date:  2013-04-11

10.  Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial.

Authors:  J F Paolini; Y B Mitchel; R Reyes; S Thompson-Bell; Q Yu; E Lai; D J Watson; J M Norquist; C McCrary Sisk; H E Bays
Journal:  Int J Clin Pract       Date:  2008-04-10       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.